Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

ZW25 > Oncology Oracle Questions > Flashcards

Oncology Oracle Questions Flashcards

1
Q

In the BTC 01 Trial the most common grade 3 adverse reaction was_________

A

Anemia 13%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

In the BTC 01 Trial the second most common grade 3 AE was _______

A

Diarrhea 9%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

In the BTC 01 Trial the third most common grade 3 AE was ________

A

Increased ALT/AST 5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

In the BTC 01 Trial the fourth most common grade 4 AE was_______

A

Fatigue 4%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

In BTC 01 the most common treatment emergent lab abnormality was_____

A

Low Hb 14%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

BTC 01 the second most common treatment emergent lab abnormality was____

A

elevated ALT 8% and elevated AST 10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

BTC 01 the third most common treatment emergent lab abnormality was_______

A

Low sodium 10%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

BTC 01 the fourth most common treatment emergent lab abnormality was _______

A

Low Lymphocytes 8%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

In BTC 01 treatment emergent AE’s led to dose reductions in______ due to_______

A

4% patients, diarrhea (3%) nausea (1%) and decreased weight (1%).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

In BTC 01 the discontinuation rate due to AE’s was _________

A

2.5%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

BTC 01 AE’s leading to permanent discontinuation were______

A

Decreased ejection fraction 1.3% and Pneumonitis 1.3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

In BTC 01 Serious AE’s occurred in_____

A

13.8% and those that occurred in >2% included diarrhea (3%) and Fatigue (3%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

With respect to the primary endpoint the ORR by ICR was________

A

41.3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

In BTC 01 Did any patients experience a CR?

A

Yes, 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Median Dor in BTC 01 was ____

A

14.9 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

In BTC 01 and Among those who were IHC 3+ and ISH amplified the cORR was____ and median DoR was____

A

52% and 15 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

In BTC 01and Among those who were IHC 2+ and ISH amplified the cORR was ____ and the median DoR was ______

A

6% and Not Evaluable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

In BTC 01 and by AJCC how many were stage 4?

A

(71) 89%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

BNTC 01 how many had greater than 1 prior line of therapy?

A

41%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

BTC 01 How many had prior Gemcitabine therapy

A

(80) 100%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

More than ___________people are diagnosed each year with BTC

A

12,000

22
Q

BTC is most often ____________ at diagnosis

A

Asymptomatic

23
Q

At diagnosis patients may experience symptoms of ________, ________, _______, ________, _________.

A

Fatigue, Weight Loss, nausea, fever or jaundice.

24
Q

Initial diagnostic tests focus on _______, ______ and _________

A

Imaging, Blood Tests, Biopsy

25
Q

An estimated _____ to ______% of patients with BTC are diagnosed when the disease is in the advanced or metastatic state

A

60-85%

26
Q

PD-L1 expression of >1% is observed in up to _____% of BTC tumors

A

70%

27
Q

Most patients with BTC remain on their First line therapy the longest, an average of _____ months

A

3.8 months

28
Q

HER2 therapies are not prescribed in the first line setting T/F?

A

T

29
Q

According to the NCCN __________ is the preferred second line therapy for BTC

A

Folfox

30
Q

MSI-H (dMMR) observed in _______ of BTC’s

A

1-3%

31
Q

HER2 overexpression or gene amplification; observed in _______% of CCA’s and ______% of GBC’s.

A

5-20%, 15-30%

32
Q

9-15% of iCCA’s harbor _______

A

FGFR2 Gene fusions or rearrangements.

33
Q

1-5% of BTC’s harbor _______

A

BRAF V600E

34
Q

10-20% of iCCA’s harbor ______

A

IDH1

35
Q

Select 1L therapies that are category 1

A

Durvalumab or Pembrolizumab +Gem/Cis,
and GEM/CIS by itself.

36
Q

Durvalumab indicated with GEM/CIS for _______

A

locally advanced and metastatic BTC

37
Q

Pembrolizumab indicated with GEM/CIS for _______

A

locally advanced, UNRESECTABLE or Metastatic BTC

38
Q

Durvalumab is a _______antibody

A

PD-L1 blocking

39
Q

Pembrolizumab is a _______ antibody

A

PD-1 blocking

40
Q

Gemcitabine (Category 2A) is a ________

A

Nucleoside Metabolic Inhibitor

41
Q

FOLFOX regimen contains _________

A

Folinic Acid - Chemotherapy Modulating Agent
Fluorouracil
Oxaliplatin

42
Q

Keytruda Monotherapy can be given first line for ______

A

MSI-H (dMMR) Category 2A

43
Q

Dosing for Durvalumab for patients >30 Kg in weight is __________

A

1500 mg +G/C every 3 weeks up to 8 cycles followed by 1500 mg every 4 weeks

44
Q

Dosing for Durvalumab for patients <30 Kg in weight is __________

A

20 mg/kg +G/C every 3 weeks up to 8 cycles followed by 20mg/kg every 4 weeks

45
Q

Durva G/C OS______, PFS______, investigator ORR______,DoR_______

A

12.8mos, 7.2 mos, 27%, 6.4 mos

46
Q

Pembro G/C OS_____, PFS _____, BICR assessed ORR_____, DoR______

A

12.7mos, 6.5 mos,29%, 8.3 mos

47
Q

Second line cat 2A Therapies include:

A

Futibatinib, Pemigatinib, Trastuzumab+Pertuzumab, Trastuzumab+Tucatinib, T-Dxd, Zanidatamab

48
Q

Futibatinib is an inhibitor of_____, and given _____mg orally 1/day

A

FGFR 1,2,3,4, 20mg

49
Q

Pemigatinib is an inhibitor of ______, and given _____mg orally 1/day

A

FGFR1,2,3, 13.5mg

50
Q

Enhertu approved in 2024 for _______

A

HER2 Positive Solid Tumors

51
Q

Enhertu dosed at______

A

5.4mg/kg

52
Q

Other choices of 2L therapy include:

A

Trastuzumab monotherapy or Trastuzumab plus pembrolizumab

ZW25 (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions